BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 16477242)

  • 1. Induction of autoimmune hepatitis by pegylated interferon in a liver transplant patient with recurrent hepatitis C virus.
    Cholongitas E; Samonakis D; Patch D; Senzolo M; Burroughs AK; Quaglia A; Dhillon A
    Transplantation; 2006 Feb; 81(3):488-90. PubMed ID: 16477242
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune-mediated liver dysfunction after antiviral treatment in liver transplanted patients with hepatitis C: allo or autoimmune de novo hepatitis?
    Merli M; Gentili F; Giusto M; Attili AF; Corradini SG; Mennini G; Rossi M; Corsi A; Bianco P
    Dig Liver Dis; 2009 May; 41(5):345-9. PubMed ID: 19162574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation.
    Kontorinis N; Agarwal K; Elhajj N; Fiel MI; Schiano TD
    Liver Transpl; 2006 May; 12(5):827-30. PubMed ID: 16628699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C.
    Ross AS; Bhan AK; Pascual M; Thiim M; Benedict Cosimi A; Chung RT
    Clin Transplant; 2004 Apr; 18(2):166-73. PubMed ID: 15016131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De novo autoimmune hepatitis after interferon treatment in a liver transplant recipient with common variable immunodeficiency.
    Aguilera I; Sousa JM; Gómez-Bravo MA; Núñez-Roldán A
    Dig Liver Dis; 2014 Jul; 46(7):663-4. PubMed ID: 24704084
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
    Zimmermann T; Böcher WO; Biesterfeld S; Zimmermann A; Kanzler S; Greif-Higer G; Barreiros AP; Sprinzl MF; Wörns MA; Lohse AW; Mönch C; Otto G; Galle PR; Schuchmann M
    Transpl Int; 2007 Jul; 20(7):583-90. PubMed ID: 17433090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic lupus erythematosus following virological response to peginterferon alfa-2b in a transplanted patient with chronic hepatitis C recurrence.
    Lodato F; Tame MR; Colecchia A; Racchini C; Azzaroli F; D'Errico A; Casanova S; Pinna A; Roda E; Mazzella G
    World J Gastroenterol; 2006 Jul; 12(26):4253-5. PubMed ID: 16830387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naïve and non-responder patients on a stable immunosuppressive regimen.
    Biselli M; Andreone P; Gramenzi A; Lorenzini S; Loggi E; Bonvicini F; Cursaro C; Bernardi M
    Dig Liver Dis; 2006 Jan; 38(1):27-32. PubMed ID: 16311084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoglobulin G4-associated de novo autoimmune hepatitis after liver transplantation for chronic hepatitis B- and C-related cirrhosis and hepatocellular carcinoma: a case report with literature review.
    Zhao XY; Rakhda MI; Wang TI; Jia JD
    Transplant Proc; 2013 Mar; 45(2):824-7. PubMed ID: 23498828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of autoimmune hepatitis by pegylated interferon alfa-2b in chronic hepatitis C.
    Lörke J; Erhardt A; Häussinger D
    Clin Gastroenterol Hepatol; 2004 Dec; 2(12):xx. PubMed ID: 15625645
    [No Abstract]   [Full Text] [Related]  

  • 11. [Antiviral therapy of patients with chronic hepatitis C with normal level of aminotransferases].
    Lopukhova NL
    Eksp Klin Gastroenterol; 2007; (4):146-52. PubMed ID: 18409502
    [No Abstract]   [Full Text] [Related]  

  • 12. [Safety of pegylated interferon in patients with hepatitis C virus induced cirrhosis].
    Gasztonyi B; Pár G; Pár A; Hunyady B
    Orv Hetil; 2005 Nov; 146(48):2431-4. PubMed ID: 16408382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination.
    Dumortier J; Scoazec JY; Chevallier P; Boillot O
    J Hepatol; 2004 Apr; 40(4):669-74. PubMed ID: 15030984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?
    Berardi S; Lodato F; Gramenzi A; D'Errico A; Lenzi M; Bontadini A; Morelli MC; Tamè MR; Piscaglia F; Biselli M; Sama C; Mazzella G; Pinna AD; Grazi G; Bernardi M; Andreone P
    Gut; 2007 Feb; 56(2):237-42. PubMed ID: 16798778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changing faces-natural course and treatment of hepatitis C after liver transplantation.
    Bahr MJ; Manns MP
    J Hepatol; 2004 Apr; 40(4):699-701. PubMed ID: 15030989
    [No Abstract]   [Full Text] [Related]  

  • 16. Pegylated interferon-2b-associated autoimmune thrombocytopenia in a patient with chronic hepatitis C.
    Sevastianos VA; Deutsch M; Dourakis SP; Manesis EK
    Am J Gastroenterol; 2003 Mar; 98(3):706-7. PubMed ID: 12650821
    [No Abstract]   [Full Text] [Related]  

  • 17. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation.
    Castells L; Vargas V; Allende H; Bilbao I; Luis Lázaro J; Margarit C; Esteban R; Guardia J
    J Hepatol; 2005 Jul; 43(1):53-9. PubMed ID: 15876467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of compensated liver cirrhosis with hepatitis C virus of genotype 1b and high viral load in whom sustained virological response was achieved by 2-year administration of very low-dose recombinant interferon alpha-2b.
    Kato H; Nakamura M; Nakamura A; Ueda R
    Eur J Gastroenterol Hepatol; 2010 Jan; 22(1):121-2. PubMed ID: 19959940
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis.
    Meyer-Wyss B; Rich P; Egger H; Helbling B; Müllhaupt B; Rammert C; Gonvers JJ; Oneta C; Criblez D; Rossi L; Borovicka J; Meyenberger C; Arn M; Renner EL;
    J Viral Hepat; 2006 Jul; 13(7):457-65. PubMed ID: 16792539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pegylated interferon alfa-2a. Improved prognosis in hepatitis C].
    MMW Fortschr Med; 2002 Sep; 144(38):59. PubMed ID: 12395712
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.